Evidence map›Paper›PMID 38693921›Full record

ArticleAnimal cells and systems2024

Suyeon Kim, Ki Wook Lee, Yongjin Yoo, Sang Hee Park, Ji Won Lee, Suhyun Jeon, Shaginyan Illia, Pooja Joshi, Hyun Woo Park, Han-En Lo and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Animal cells and systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Role of non-coding RNAs in OOncology letters · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Suyeon KimDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Ki Wook LeeDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Yongjin YooDepartment of Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA, USA.
Sang Hee ParkDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Ji Won LeeDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Suhyun JeonDepartment of Biosciences, Mokpo National University, Muan, Republic of Korea.
Shaginyan IlliaDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Pooja JoshiDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Hyun Woo ParkDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Han-En LoDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Jimin SeoDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Yeonwoo KimDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Min ChangDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Tae Jin LeeDepartment of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Jong Bae SeoDepartment of Biosciences, Mokpo National University, Muan, Republic of Korea.
Sung-Hak KimDepartment of Animal Science, Chonnam National University, Gwangju, Republic of Korea.
Carlo M CroceDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Inki KimASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
Sung-Suk SuhDepartment of Biosciences, Mokpo National University, Muan, Republic of Korea.
Young-Jun JeonDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Sungkyunkwan University · KRMokpo National University · KRAsan Medical Center · KRCalifornia Institute for Regenerative Medicine · USCancer Genetics (United States) · USThe Ohio State University · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has chemotherapeutic potential as a regulator of an extrinsic apoptotic ligand, but its effect as a drug is limited by innate and acquired resistance. Recent findings suggest that an intermediate drug tolerance could mediate acquired resistance, which has made the main obstacle for limited utility of TRAIL as an anti-cancer therapeutics. We propose miRNA-dependent epigenetic modification drives the drug tolerant state in TRAIL-induced drug tolerant (TDT). Transcriptomic analysis revealed

Indexed as

lung cancerMicroRNAsRSK2TRAIL-persistence

Identifiers

PMID38693921
PMCPMC11062278
OpenAlexW4396515264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.